Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Evaluating the use of microelectrode array technology and cell-based neuronal culture models for proconvulsant risk assessment: progress from the HESI NeuTox consortium.

Millard DC, Nicolini AM, Arrowood CA, Hayes HB, Bradley JA, Strock CJ, Freudenrich TM, Wallace K, Shafer TJ, Cato MJ, Chaudhary KW, Saavedra L, Haag D, Feaster TK, Anson BD, Luerman G, Hess D, Shi Y, Li J, Shi H, Levesque P, Kreir M, Lu HR, Suzuki I, Odawara A, Miyamoto N, Ojima A, Kanda Y, Blinova K, Herr D, Roberts R, Pierson J.

J Pharmacol Toxicol Methods. 2019 Sep - Oct;99:106595. doi: 10.1016/j.vascn.2019.05.076. Epub 2019 Oct 17. No abstract available.

PMID:
31963054
2.

Identification of Drug-Drug Interactions In Vitro: A Case Study Evaluating the Effects of Sofosbuvir and Amiodarone on hiPSC-Derived Cardiomyocytes.

Millard DC, Strock CJ, Carlson CB, Aoyama N, Juhasz K, Goetze TA, Stoelzle-Feix S, Becker N, Fertig N, January CT, Anson BD, Ross JD.

Toxicol Sci. 2016 Nov;154(1):174-182. Epub 2016 Aug 7.

PMID:
27503387
3.

Development and Characterization of a Scaffold-Free 3D Spheroid Model of Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes.

Beauchamp P, Moritz W, Kelm JM, Ullrich ND, Agarkova I, Anson BD, Suter TM, Zuppinger C.

Tissue Eng Part C Methods. 2015 Aug;21(8):852-61. doi: 10.1089/ten.TEC.2014.0376. Epub 2015 Mar 16.

PMID:
25654582
4.

High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents.

Ma J, Guo L, Fiene SJ, Anson BD, Thomson JA, Kamp TJ, Kolaja KL, Swanson BJ, January CT.

Am J Physiol Heart Circ Physiol. 2011 Nov;301(5):H2006-17. doi: 10.1152/ajpheart.00694.2011. Epub 2011 Sep 2.

5.

Opportunities for use of human iPS cells in predictive toxicology.

Anson BD, Kolaja KL, Kamp TJ.

Clin Pharmacol Ther. 2011 May;89(5):754-8. doi: 10.1038/clpt.2011.9. Epub 2011 Mar 23. Review. No abstract available.

6.

Stem cells and their derivatives: a renaissance in cardiovascular translational research.

Kattman SJ, Koonce CH, Swanson BJ, Anson BD.

J Cardiovasc Transl Res. 2011 Feb;4(1):66-72. doi: 10.1007/s12265-010-9235-1. Review.

PMID:
21061105
7.

Properties of WT and mutant hERG K(+) channels expressed in neonatal mouse cardiomyocytes.

Lin EC, Holzem KM, Anson BD, Moungey BM, Balijepalli SY, Tester DJ, Ackerman MJ, Delisle BP, Balijepalli RC, January CT.

Am J Physiol Heart Circ Physiol. 2010 Jun;298(6):H1842-9. doi: 10.1152/ajpheart.01236.2009. Epub 2010 Apr 2.

8.

Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Rajamani S, Eckhardt LL, Valdivia CR, Klemens CA, Gillman BM, Anderson CL, Holzem KM, Delisle BP, Anson BD, Makielski JC, January CT.

Br J Pharmacol. 2006 Nov;149(5):481-9. Epub 2006 Sep 11.

9.

Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism.

Anderson CL, Delisle BP, Anson BD, Kilby JA, Will ML, Tester DJ, Gong Q, Zhou Z, Ackerman MJ, January CT.

Circulation. 2006 Jan 24;113(3):365-73.

PMID:
16432067
10.

Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy.

Kawakami K, Nagatomo T, Abe H, Kikuchi K, Takemasa H, Anson BD, Delisle BP, January CT, Nakashima Y.

Br J Pharmacol. 2006 Mar;147(6):642-52.

11.

Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr).

Rajamani S, Anderson CL, Valdivia CR, Eckhardt LL, Foell JD, Robertson GA, Kamp TJ, Makielski JC, Anson BD, January CT.

Am J Physiol Heart Circ Physiol. 2006 Mar;290(3):H1278-88. Epub 2005 Oct 14.

12.

Intragenic suppression of trafficking-defective KCNH2 channels associated with long QT syndrome.

Delisle BP, Slind JK, Kilby JA, Anderson CL, Anson BD, Balijepalli RC, Tester DJ, Ackerman MJ, Kamp TJ, January CT.

Mol Pharmacol. 2005 Jul;68(1):233-40. Epub 2005 Apr 25.

PMID:
15851652
13.

Blockade of HERG channels by HIV protease inhibitors.

Anson BD, Weaver JG, Ackerman MJ, Akinsete O, Henry K, January CT, Badley AD.

Lancet. 2005 Feb 19-25;365(9460):682-6.

PMID:
15721475
14.

An intronic mutation causes long QT syndrome.

Zhang L, Vincent GM, Baralle M, Baralle FE, Anson BD, Benson DW, Whiting B, Timothy KW, Carlquist J, January CT, Keating MT, Splawski I.

J Am Coll Cardiol. 2004 Sep 15;44(6):1283-91.

15.

Biology of cardiac arrhythmias: ion channel protein trafficking.

Delisle BP, Anson BD, Rajamani S, January CT.

Circ Res. 2004 Jun 11;94(11):1418-28. Review.

PMID:
15192037
16.

Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels.

Anson BD, Ackerman MJ, Tester DJ, Will ML, Delisle BP, Anderson CL, January CT.

Am J Physiol Heart Circ Physiol. 2004 Jun;286(6):H2434-41. Epub 2004 Feb 19.

17.

Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C.

Delisle BP, Anderson CL, Balijepalli RC, Anson BD, Kamp TJ, January CT.

J Biol Chem. 2003 Sep 12;278(37):35749-54. Epub 2003 Jul 1.

18.
19.

Genetic basis for the origin of cardiac arrhythmias: implications for therapy.

Mbai M, Rajamani S, Delisle BP, Anson BD, Anderson C, Makielski JC, January CT.

Curr Cardiol Rep. 2002 Sep;4(5):411-7. Review.

PMID:
12169238
20.

Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block.

Rajamani S, Anderson CL, Anson BD, January CT.

Circulation. 2002 Jun 18;105(24):2830-5.

PMID:
12070109
21.
22.
23.

Effects of protein and juglone on gypsy moths: Growth performance and detoxification enzyme activity.

Lindroth RL, Anson BD, Weisbrod AV.

J Chem Ecol. 1990 Aug;16(8):2533-47. doi: 10.1007/BF01017476.

PMID:
24264218

Supplemental Content

Loading ...
Support Center